KALAMAZOO, Mich.--(BUSINESS WIRE)--ProNAi Therapeutics, Inc., a pioneer in developing a novel class of drugs based on DNA interference (DNAi), today announced that it has built up its leadership team, adding a veteran CEO and top R&D and management executives with long track records of success in life sciences.
